William Blair analyst Myles Minter downgraded Vigil Neuroscience (VIGL) to Market Perform from Outperform without a price target after the company agreed to be acquired by Sanofi for $ per share upfront.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
- Vigil Neuroscience Inc trading halted, news pending
- Vigil Neuroscience Advances Clinical Trials and Financial Stability
- Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year